Human natural killer (NK) cells are built to kill abnormal cells but to preserve autologous normal cells. To accomplish this task, they are equipped with a large number of inhibiting and activating receptors. Ligation with corresponding ligands will determine whether the NK cell becomes activated to destroy the abnormal cell. This review will focus on the abnormalities of NK cell receptors and their putative ligands found in patients with leukemia, which can lead to an inadequate function of NK cells allowing these malignant cells to escape from NK cell destruction. In recent years it has become clear that NK cells in the haploidentical hematopoietic stem cell transplantation (HSCT) setting are very effective in eliminating residual acute myeloid, but not acute lymphoid, leukemic cells. In this regard, we also reviewed published studies of retrospective cohorts of HSCT investigating the potential beneficial effect of killer-cell immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) ligands on NK alloreactivity. Manipulating NK cell inhibition or activation could lead to new forms of immunotherapy, ultimately leading to the elimination of resistant leukemic cells.
Introduction
The ability of natural killer (NK) cells to destroy leukemic cells as demonstrated by allogeneic transplantation of hematopoietic stem cells indicates that this cell type is implicated in the control and clearance of leukemia. 1, 2 The number or activity of autologous NK cells against leukemic cells is frequently reduced and abnormalities at the level of receptors and/or ligands determining NK cell function may be responsible for the resistance of leukemic cells to NK cells. [3] [4] [5] [6] [7] [8] [9] There is also still a high occurrence of leukemic relapse after high dose chemotherapy and/or allogeneic hematopoietic stem cell transplantation (HSCT), suggesting that leukemic cells can escape from the immune system. A variety of studies are now ongoing to unravel the mechanisms of NK cell killing of leukemic targets and to explain how leukemia can escape from the innate immune surveillance. This overview summarizes the most important findings available from the literature about the role of NK cell receptors and their ligands in the immunity against different types of leukemia. Further understanding of the NK receptor biology is necessary to develop therapeutic strategies that may create an efficient NK cell immune response against leukemia.
Role of inhibitory KIRs and HLA class I interactions
The activity of NK cells is controlled by the expression of inhibitory receptors that interact with human leukocyte antigen (HLA) class I molecules. Prominent among these HLA class Ispecific receptors are the killer cell immunoglobulin-like receptors (KIRs), which are encoded by a diverse and rapidly evolving family of different polymorphic genes. Within the human population, the variation of KIR haplotypes depends on the number and type of KIR genes that they inherited and on the allelic polymorphism. Consequently, diverse KIR repertoires are generated across individuals with differences in the balance between activating and inhibitory receptors, which may influence the NK and/or T-cell activity to lyse tumor targets.
Only scant information is available from the literature concerning the role of KIR and HLA genes in the pathogenesis of leukemia. Here our study found an increased frequency of specific inhibitory KIR-HLA class I interactions in different forms of leukemia compared to the healthy volunteers. 10, 11 This data suggests that one escape mechanism from the innate immune surveillance might be due to a dominance of inhibitory over activating signals in leukemic patients. Along this line, a recent study demonstrated that B lineage chronic lymphoid leukemia (B-CLL) patients with advanced disease had significantly higher percentages of cytotoxic T cells expressing inhibitory KIRs and CD94 compared to B-CLL patients with nonprogressive disease. 12 In patients with chronic myeloid leukemia (CML) the number of NK cells progressively decrease during disease progression. 4, 5 Substantial numbers of NK cells in an advanced phase of the disease were found to be positive for t (9;22) translocation-related breakpoint cluster region-abelson (BCR/ ABL) in contrast to those in the chronic phase. 5, 13 It has been demonstrated that BCR/ABL can increase KIR expression and so influence the activity of NK cells. 13 The importance of inhibitory KIR-HLA class I interactions in the innate immune response against leukemic cells has been further underscored in allogeneic HLA-mismatched HSCT. In the setting of KIR ligandmismatched HSCT, NK cell alloreactions are directed toward allogeneic cells that lack inhibitory HLA class I ligands. A fraction of the donor NK cells may only express inhibitory KIRs that are not engaged by the HLA class I alleles of the recipient, and thus have the potential to kill the residual leukemic cells of the patient. In this context, a study published by Koh et al. 14 demonstrated that antibody blockade of murine NK inhibitory receptors enhanced the lysis of leukemic cells both in vivo and in vitro, supporting a pivotal role of NK inhibitory receptors in decreasing the anti-leukemic NK cell response.
Cell surface expression of HLA class I molecules
Normal cells express a threshold of HLA class I molecules that protect them from autologous NK cell killing, whereas malignant cells often have a reduced expression or loss of HLA class I alleles and therefore become susceptible to NK cells. Most types of solid tumors display defects in HLA class I expression, but the incidence of HLA class I downregulation and complete HLA class I allele loss varies among different types of tumors. 15 In contrast to solid tumors, HLA class I expression in leukemia has not been extensively studied, except in acute leukemia [16] [17] [18] [19] [20] and B-CLL. 21 In most of these studies, complete loss of HLA class I allele(s) in leukemic cells was infrequent. A possible explanation for this low frequency is that the time interval between the onset of leukemia and the diagnosis is too short to permit leukemic cells to acquire mutations in the genes involved in HLA class I expression. On the other hand, our group has reported frequent partial downregulation of certain HLA class I alleles on leukemic cells in comparison with their normal autologous cells. 19 At variance with complete loss, downregulation of HLA class I alleles is rather caused by defects in regulatory mechanisms and is generally restored by cytokines. 17 In the other studies, it is likely that the frequency of HLA class I allelic downregulation was underestimated 16, 18, 21 since labeling of leukemic cells was done with a few anti-allelic mAbs or recognizing monomorphic determinants of HLA class I antigens that do not detect downregulation of HLA class I expression at the allelic level. Our study on a heterogeneous group of leukemia further showed that HLA class I molecules belonging to the Bw6 group were more frequently downregulated than those belonging to the HLA-Bw4 group. 19 Since HLA-B molecules containing the serologically defined Bw6 epitope cannot be sensed by NK cells, downregulation of HLA-Bw6 may provide leukemic cells with an escape mechanism only from cytotoxic T cells. 19 Leukemic cells with a downregulated HLA-Bw6 expression and a preserved HLA-Bw4 expression inhibiting NK cells, can therefore escape from both cytotoxic T cells and NK cells.
Until now, the expression of HLA-C on leukemic cells, which interacts with the majority of inhibitory KIRs, has not been studied. We recently analyzed the expression of certain HLA-C alleles (Cw1, Cw3, Cw4, Cw0801, Cw1202 and Cw1402) on acute myeloid leukemia (AML), B lineage acute lymphoblastic leukemia (B-ALL) and B-CLL cells. Our study demonstrates that HLA-C expression was significantly downregulated in all three types of leukemic patients and was most pronounced in the AML patients (unpublished data).
The aberrant expression of nonclassical HLA class I antigens on tumor cells may provide a further escape mechanism from the immune response by interacting with inhibitory receptors on NK cells and certain T-cell subsets. HLA-G is a nonclassical HLA class I molecule recognizing KIR2DL4, which is not expressed by normal cells with the exception of trophoblast tissue. In addition to its inhibitory function, KIR2DL4 can also have an activating function that may depend on the type of cell. 22 Despite the presence of HLA-G transcription in mature lymphoid cells, HLA-G antigens are not expressed at the cell surface of normal lymphocytes or leukemic cells in the absence of IFN-g. [23] [24] [25] This finding is at variance with a study published by Nuckel et al. 26 showing that a variable percentage of CLL-B cells aberrantly expressed the nonclassical HLA-G molecule. The surface expression of HLA-E depends on the binding of peptides derived from HLA class I molecules. In general, HLA-E surface expression correlates with the overall expression of HLA class I molecules and can be recognized by the inhibitory NKG2A receptor. In contrast to cells from healthy volunteers, HLA-E is not transcribed and hence not expressed in different types of leukemia. 27 Immunotherapy based on preventing NK cell inhibition Hematopoietic stem cell transplantation HSCT has been used for several years to cure leukemic patients. However graft failure, graft-versus-host disease (GvHD), leukemic relapse and susceptibility to infections remain significant complications that limit the efficacy of HSCT.
Before the infusion of hematopoietic stem cells (HSC), recipients undergo a myeloablative conditioning regimen to destroy the host immunohematopoietic system, suppressing its immune system, making space for the donor HSC and reducing the tumor burden in the patient. Afterwards, the infused HSC will differentiate and proliferate to reconstitute a new immunohematopoietic system of donor type. The lymphocytes, particularly T cells, in the graft further eliminate host T cells, preventing rejection and destroying residual leukemic cells that survive the conditioning regimen, thereby decreasing the rate of relapse. The risks of graft rejection, caused by host T-cell recognition of donor HLA, and that of GvHD, caused by donor recognition of host HLA antigens, are augmented with increasing numbers of HLA mismatches. 28 Thus the success of HSCT depends on the degree of HLA matching between the donor and recipient and the best clinical outcome occurs when patients are transplanted with a graft from an HLA-identical sibling. However only a minority of patients will find a fully HLA-matched donor, because there is only a 25% chance that siblings are HLA identical. So leukemic patients who failed to find a related or unrelated HLA-matched donor can be given a transplant from an HLA-haploidentical family member. But HLA-haploidentical transplants, in which the donor and recipient are incompatible at the HLA loci of the unshared haplotype, are at high risk for T-cell-mediated alloreactions. Therefore T-cell-mediated graft rejection can only be prevented by a high intensity conditioning regimen destroying the host T cells, followed by the infusion of equal to or more than 10 Â 10 6 CD34 þ cells per kg of HSC. In addition, extensive T-cell depletion of the graft is required to control GVHD. In contrast to the HLA-matched transplants, the GvL effect in these haploidentical transplants relies on alloreactivity of NK cells triggered by a mismatch between the inhibitory KIRs on the donor NK cells and the HLA class I molecules on the recipient cells. Because most individuals express all inhibitory KIR genes, a potential for NK cell alloreactivity is present when the recipient does not express the donor's KIR ligand(s) in the haploidentical HSCT setting. For example, when the donor is heterozygous for HLA-C group 1 (HLA-C1) and group 2 (HLA-C2), this donor will have usually the inhibitory KIR2DL2/3 and KIR2DL1 for these HLA-C ligands. Transplanting a graft from this donor into a patient who is homozygous for HLA-C1 or HLA-C2 will result in alloreactive donor NK clones with inhibitory KIRs that cannot bind the HLA-C ligand on the recipient cells. However this cannot be applied to one-third of the patients who express all three KIR ligands (HLA-C1, HLA-C2 and HLA-Bw4) and consequently inhibit NK cells from every donor. A recent study published by Kim et al. 29 proposed that only immature NK cells expressing an inhibitory receptor that can engage self HLA class I molecules, become fully functional. Thus donor NK cells expressing solely inhibitory KIRs for self HLA class I molecules that are present in the donor and not in the recipient sense the missing selfexpression of HLA and can therefore mediate alloreactions. The first study that demonstrated that KIR ligand incompatibility could reduce the risk of relapse, promote engraftment and protect against GvHD in AML patients transplanted with a graft from related haploidentical donors was published by Ruggeri et al.,
2 which is confirmed in their later study. 30 After this initial study, additional studies retrospectively analyzed cohorts of related 31 and unrelated [32] [33] [34] [35] [36] [37] [38] [39] HLA-mismatched HSCT to address the impact of NK alloreactivity on different transplant outcome variables (an overview is given in Table 1 ). A second study of related haploidentical transplants published by Bishara et al. 31 failed to confirm any beneficial effect of KIR ligand incompatibility. The impact of KIR ligand incompatibility has also been controversial for unrelated HSCT. Only two studies in unrelated HSCT observed a decreased leukemic relapse rate in patients with myeloid leukemia receiving a graft from KIR ligand incompatible donors. 33, 36 In the study published by Giebel et al., 33 all patients received anti-thymocyte globulin (ATG) during the conditioning regimen resulting in vivo depletion of patient and donor T cells. The results showed that the use of ATG favored the beneficial effects of alloreactive NK cells. However several other retrospective HSCT studies could not confirm these beneficial effects of KIR ligand incompatibility despite the use of ATG. 34, 35, 37, 38 In contrast, some reports found that KIR ligand incompatibility was even associated with an increased rate of treatment-related mortality (TRM) caused by infection. 35, 37, 38 A possible mechanism underlying the increased infection-related mortality in these patients is that donor alloreactive NK cells may kill the patient's dendritic cells and in this way interfere with immunity against opportunistic infections.
Because KIR and HLA segregate independently from each other, an individual can also express an inhibitory KIR but no HLA ligand for that KIR. In this way the missing KIR ligand can also be applied in HLA-matched HSCT, where the donors express inhibitory KIRs for which neither donor nor recipient has HLA class I ligand(s). Normally, NK clones that express inhibitory KIRs in the absence of self-HLA class I ligands are self-tolerant. However, one study showed that these NK clones are still active but because this NK cell population persists at a low frequency in a person's blood, these cells cannot cause autoreactions. 39 It has been postulated that these NK clones after transplantation, which, on expansion in an altered hematopoietic environment, may become alloreactive. Only a few studies took into account the interactions between KIRs on donor NK cells and recipient HLA ligands to study NK alloreactivity on transplant outcome. 30, 38, 41, 42, 44 In related HLA-matched HSCT, Hsu et al. 42 demonstrated that AML and myelodysplastic syndrome (MDS) patients who lacked the HLA ligand for the donor KIR genotype had significantly increased disease-free and overall survival. The same beneficial effect was recently observed in early stage myeloid leukemia patients who lacked one of the KIR ligands. 43 In contrast, an inferior survival was observed in patients who were homozygous for HLA-C2, but only when donors were positive for the activating KIR2DS2 receptor. 41 Although the importance of inhibitory KIRs has been extensively investigated in HLA-mismatched HSCT, the role of activating KIRs has only been studied in a few other HSCT studies. 38, 41, [44] [45] [46] Our study in related HLA-identical HSCT observed that the incidence of relapse decreased when patients received a graft from activating KIR2DS1 and KIR2DS2 positive donors. 44 Furthermore, Giebel et al. 46 found that the presence of KIR2DS2 alone in the donor was associated with a high risk of mortality following unrelated HSCT, presumably caused by a higher incidence of GvHD. Finally, a study published by Gagne et al. 45 showed that the risk for GvHD was very high when the KIR genotype of an unrelated donor included activating KIRs that were absent in the recipient KIR genotype.
Taken together, these studies show that not only KIR ligand incompatibility but also the number of activating KIRs 38 and presence of particular activating KIRs in the donor might influence transplant outcome (Table 1) . In contrast to haploidentical HSCT, KIR ligand incompatibility is mostly not associated with a decreased relapse in unrelated HSCT (Table 1) . Heterogeneity in the treatment procedures (conditioning regimen, graft composition and post-transplant immune suppression) and in the patient population (disease, risk category) might explain the conflicting results concerning KIR ligand incompatibility (Table 2 ). More specifically, unrelated grafts contain more T cells than haploidentical grafts and this has been shown to be associated with poor reconstitution of potentially alloreactive NK cells. Prospective studies in the unrelated setting should therefore include functional assessment of donor NK alloreactivity toward leukemic targets besides a more extensive T-cell depletion of the graft.
Immunotherapy using the NK-92 cell line
A novel attractive immunotherapy for the treatment of leukemia is the use of the NK-92 cell line because it has a superior antitumor effect against a broad range of human leukemic cell lines in vitro, albeit with a variable activity against B-ALL cells. [47] [48] [49] The NK-92 cell line is an IL-2 dependent cell line isolated from a patient with non-Hodgkin's lymphoma at diagnosis. The high cytotoxicity of the NK-92 cell line is thought to be the result of an almost complete lack of inhibitory KIRs with a preserved perforin-and granzyme-mediated cytotoxicity. Consequently, in vivo administration of this NK cell line in allogeneic leukemic patients could create a KIR ligand mismatch situation similar to that encountered in an allogeneic HSCT. Moreover, studies showed that leukemic blasts from B-ALL patients were more resistant to killing by the NK-92 cell line than the other types of leukemia. [47] [48] [49] It has also been demonstrated that the NK-92 cell line does not induce cytotoxicity toward normal bone marrow cells, suggesting that malignant hematopoietic cells express additional activating ligands and that resistance of certain leukemic cells could be caused by the absence or downregulated expression of these NK activating ligands. 47, 50 In this regard, a study established that the NK-92 cell line could be used as a purging agent to decrease or eliminate the malignant contamination of autologous stem cell grafts in CML patients. 51 Other clinical trials are currently underway using NK-92 for adoptive immunotherapy of malignancies. 52 
Role of activating NK cell receptors and their ligands
Although the interaction of inhibitory NK cell receptors with HLA class I molecules controls the NK cell activation, it is apparent that an activating signal is needed when NK cells interact with potential leukemic cells. Resistance of leukemic cells against NK cells mediated by inhibitory KIR-HLA class I interaction may therefore be further increased by additional mechanisms based on defective activating NK receptor-ligand interactions.
An important tumor escape mechanism from immune surveillance is the absence or downregulation of specific activating antigens. Certain types of leukemia are resistant to NK cells of an allogeneic KIR ligand-mismatched donor. In this regard, a significant graft-versus-leukemia effect was observed in AML patients but not in B-ALL patients following haploidentical HSCT. 2 It has also been shown that B-ALL cells are negative for the MHC class I-related protein (MICA/B) ligands known to trigger the NKG2D receptor and loose or express low levels of several other NK activating ligands such as PVR, Nectin-2, CD48 and NK-T-B antigen (NTBA) ( Table 3) . 49, 53 Presumably, downregulated expression of other unidentified ligands for NK The recipient KIR genotype is included in the donor KIR genotype when the donor has KIR genes supplementary to those of the recipient.
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activating receptors, including the natural cytotoxicity receptors (NCRs) or the polymorphic KIRs, may be involved in the NK resistance of B-ALL. This data suggests that resistance of most B-ALL cells to NK cells in haploidentical HSCT maybe caused by the lack of expression of crucial activating ligands.
It was recently shown that AML cells are negative for or have low levels of the NKG2D ligands (MICA/B and unique long 16-binding proteins (ULBP)) and the putative NCR ligands 53, 54 and that this could be caused by cell maturation arrest during malignant transformation. 54 By contrast, the levels of ULBP and NCR ligands on normal myeloid cells are higher because they increase during hematopoietic cell differentiation. 54 These normal myeloid cells would be protected against lysis by autologous NK cells by the expression of HLA class I molecules interacting with the inhibitory KIRs. However, antibodymediated blockade of activating receptor pathways revealed a dominant role for DNAX accessory molecule-1 (DNAM-1) and NCRs, but a complementary contribution of NKG2D signaling in AML cell recognition. 6, 53 The importance of the activating DNAM-1 receptor in the lysis of AML blasts was also confirmed by the consistent expression of PVR and nectin-2 ligands on their cell membrane. 53 This was at variance with the study published by Salih et al. 55 who found that a substantial number of AML patients expressed NKG2D ligands that can render leukemic cells susceptible to NK cells. Taken together, these studies suggest that the leukemic blasts of most AML patients express ligands able to trigger allogeneic NK cells. But there are still conflicting results on the importance of the activating NKG2D in the lysis of AML cells. 53, 55 An upregulation of NKG2D ligands on leukemic cells by growth factors could enhance NK cellmediated killing. 7 An overview of the expression of different NK activating ligands on AML cells is given in Table 3 . Furthermore, Costello et al. 6, 56 demonstrated that the majority of NK cells in AML patients display a low NCR surface density correlating with their weak cytolytic activity against autologous leukemic cells. Downregulation of the activating receptors on NK cells from AML patients may explain the observed reduced NK killing of autologous AML cells and the HLA class I-deficient K562 cell line. 6, 7, 9, 56 Unfortunately, the expression of the activating DNAM-1 receptor on NK cells from AML patients has not yet been analyzed. It has also been suggested that direct cell contact between leukemic blasts and NK cells rather than secretion of TGF-b 1 may induce downregulation of the NCRs. 56 High levels of soluble MICA/B have been found in the serum of patients with AML 55 and CML 57 and might cause downregulation of the activating NKG2D receptor. 58, 59 Nevertheless a In contrast to AML patients, most CML patients express high levels of MICA/B molecules. 57 Blocking experiments with anti-NKG2D showed that the activating NKG2D receptor plays an important role in the killing of CML cells and might be able to override the inhibitory signals provided by the KIR-HLA interactions. 57 Some of the CML patients expressed reduced levels of the NKG2D receptor, which could explain why autologous NK cells display a decreased killing of CML cells.
Finally, there are limited studies concerning the role of the NK activating pathway in B-CLL patients. However, one study reported that the inability of gd T cells to efficiently kill autologous leukemic B cells might be attributable to the lack of ligands for the activating NKG2D receptor. 60 
Immunotherapy based on increasing NK cell activation

Cytokines
It has been demonstrated that the addition of cytokines, particularly IL-2, has the capacity to increase NK cell proliferation and to kill NK cell-resistant cell lines and human tumor cells of different types. The first clinical trials started in the 1980s, comparing IL-2 alone to IL-2 with autologous ex vivo IL-2 expanded and activated lymphokine-activated killer (LAK) cells in patients with advanced solid tumors. 61 Generally, no significant beneficial effects were observed with the addition of LAK cells and IL-2 based immunotherapies were mostly associated with severe toxic effects.
Although it has been demonstrated that autologous LAK cells have the capacity to kill leukemic cells in vitro, 62, 63 only a few clinical trials transplanting autologous LAK cells have been reported for the treatment of leukemia. [64] [65] [66] [67] [68] However, transplantation of autologous LAK cells showed a limited antileukemic effect in the patients. No definitive conclusion can be drawn because of the limited numbers of patients with poor prognosis included in these studies. In contrast to IL-2, IL-15 upregulates, the anti-apoptotic protein Bcl-2 that gives IL-15-stimulated NK cells a survival advantage. 69 Administration of IL-15 can therefore increase immune reconstitution following transplantation, because it plays a pivotal role in the survival of NK cells, leading to increased NK cell numbers. 70 The cytokines IL-12 and IL-18 induce IFN-g production in NK cells. 71 Another cytokine that has the ability to activate NK cells is IL-21. This cytokine plays an important role in the maturation of NK cells and thus allows the induction of full NK cell maturation. 72 Finally, it has been shown that combinations of different cytokines at low doses are associated with a synergistic antitumor effect and lower toxicity and hence could be used as immune therapy for treatment of leukemia. 73 
Upregulating the activating NK cell receptors or ligands
The recent understanding of the importance of activating NK receptors in the recognition and killing of leukemia cells suggests new therapeutic strategies. The functional activity of NK cells is regulated by an array of distinct inhibitory and activating receptors integrating a balance between negative and positive signals that decides whether the NK cell will be inhibited or activated. Modulating the balance toward activation by upregulating NK activating receptors can induce NK cell cytotoxicity. However there is limited knowledge about how we Abbreviations: MICA/B, major histocompatibility complex class I chain-related molecules A and B; NCR, natural cytotoxicity receptors; PVR, poliovirus receptor; ULBP, unique long 16-binding proteins.
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can modulate the expression of NK cell activating receptors. It is generally accepted that IL-2 induces the expression of the activating NKp44 receptor on NK cells. 74 Different cytokines, including IL-2, IL-15 and IL-18, have been shown to increase the expression of activating NKG2D. 75, 76 On the other hand, it is possible that the administration of cytokines activates NK cells but also increases the inhibitory signals that counterbalance any NK cell activation. In this context it has been shown that IL-15 not only upregulates the activating NKG2D receptor but also provides an appropriate stimulus for the expression of the inhibitory CD94/NKG2A receptor. 77 IL-21 induces rapid and full maturation by which NK cells express various NK receptors such as the NKp46 and NKp30 triggering receptors, CD16, 2B4 and the inhibitory CD94/NKG2A and KIRs. 72 Conversely, IL-21 has the ability to downregulate NKG2D/DAP10 expression that correlates with a downregulated NK cell function. 78 An alternative approach to augment NK lysis is the upregulation of NK activating ligands on the tumor cell surface. Leukemic blasts in AML patients express very low levels of ULBP ligands. Treatment with hematopoietic differentiationpromoting agents, myeloid growth factors, together with IFN-g, upregulates the cell surface levels of ULBP1 on AML blasts, increasing their susceptibility to NK cell-mediated lysis.
54,79
Antibodies
The majority of NK cells express the FcgRIII (CD16) receptor that binds to the Fc component of the IgG antibody bound on the target cell surface. Upon binding of the Fc receptor, NK cells are activated, leading to degranulation and secretion of cytotoxic granules that kill the target cell. In this regard, chimeric IgG antibodies against specific antigens present on leukemic cells have been used to induce ADCC against these leukemic cells. [80] [81] [82] Another therapeutic approach is the application of bispecific antibodies to link NK cell activating receptors with tumor cells. In this regard, an antibody against CD16 and CD19 has been developed to target B non-Hodgkin's lymphoma. 83 
Conclusion
Further studies considering both inhibitory and activating NK cell pathways are needed to identify the exact innate immune escape mechanism used by each type of leukemia. In this way, an efficient NK cell immune response, by either blocking inhibitory KIR-HLA or by upregulating activating NK cell receptor-ligand interactions, or by both, could be developed against these different forms of leukemia. The importance of inhibitory KIR and HLA class I genes in susceptibility to leukemia has been underscored. So one approach to increase NK cell killing of leukemic targets would be to block specific inhibitory KIRs-HLA interactions so that the inhibitory signal could be removed. On the other hand, we observed that partial downregulation of HLA class I allele expression occurs frequently in leukemic cells. This observation raises an important question as to how much HLA class I is needed to be expressed to inhibit NK cells. More functional tests with leukemic cells expressing a decreased KIR ligand level have to be performed in the future, to correlate HLA-C or/and -Bw4 expression with NK cell function. Moreover, leukemic cells might also use other resistance mechanisms such as downregulation of ligands for activating receptors on NK cells and/or T cells. In this regard, a positive outcome of inhibitory KIR-HLA mismatch has been demonstrated in patients with myeloid leukemia, while patients with B-ALL seem not to benefit from this NK alloreactivity. The difference observed in susceptibility of AML and ALL cells to NK alloreactivity can be explained by insufficient levels of ligands on ALL cells that are necessary for NK cell-mediated killing. Modulating the balance toward activating signals through upregulation of the activating NK cell ligands on the acute lymphoid blasts could therefore enhance NK killing.
